India covid-19 information patient India

Biocon’s itolizumab fails to be part of Covid-19 management protocols

Reading now: 414
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.The National Task Force for Covid-19 in India has denied inclusion of Biocon’s itolizumab in its clinical management protocols for the disease.

Earlier this month, the drug received emergency use authorisation from the Drugs Controller General of India (DCGI) to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) patients with Covid-19.

The drug is an anti-CD6 IgG1 monoclonal antibody introduced in India in 2013 under the brand name ALZUMAb to treat chronic plaque psoriasis.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA